Published in Am Surg on September 01, 2017
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A (2005) 3.49
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Updat (2003) 2.07
Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis (2008) 1.96
The use of immunoglobulin g4 immunostaining in diagnosing pancreatic and extrapancreatic involvement in autoimmune pancreatitis. Clin Gastroenterol Hepatol (2007) 1.83
External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme. Am J Clin Pathol (2009) 1.57
Recent advances in operant conditioning technology: a versatile and affordable computerized touchscreen system. Behav Res Methods Instrum Comput (2004) 1.30
Digital slides: present status of a tool for consultation, teaching, and quality control in pathology. Pathol Res Pract (2009) 1.29
Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother (2008) 1.25
Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol (2009) 1.23
Comparison of assays for detection of agents causing membrane damage in Staphylococcus aureus. J Antimicrob Chemother (2004) 1.22
Anti-staphylococcal activity and mode of action of clofazimine. J Antimicrob Chemother (2004) 1.17
XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms. J Antimicrob Chemother (2010) 1.04
Biological properties of novel antistaphylococcal quinoline-indole agents. Antimicrob Agents Chemother (2003) 0.97
Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee. Appl Immunohistochem Mol Morphol (2015) 0.97
Ectopic prostatic tissue in the uterine cervix and vagina: report of a series with a detailed immunohistochemical analysis. Am J Surg Pathol (2006) 0.95
XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity. J Antimicrob Chemother (2009) 0.95
TRISS unexpected survivors: an outdated standard? J Trauma (2002) 0.94
Spitz nevus with Homer-Wright rosette-like structures. Am J Dermatopathol (2012) 0.88
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. J Exp Clin Cancer Res (2012) 0.88
Furanyl-rhodanines are unattractive drug candidates for development as inhibitors of bacterial RNA polymerase. Antimicrob Agents Chemother (2010) 0.87
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists. J Med Chem (2009) 0.83
Zeocin resistance suppresses mutation in hypermutable Escherichia coli. Microbiology (2003) 0.83
Effective triage can ameliorate the deleterious effects of delayed transfer of trauma patients from the emergency department to the ICU. J Am Coll Surg (2009) 0.83
A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. Am J Clin Pathol (2011) 0.82
External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J Clin Pathol (2006) 0.82
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories. Appl Immunohistochem Mol Morphol (2017) 0.82
Rapid multiplexed flow cytometric assay for botulinum neurotoxin detection using an automated fluidic microbead-trapping flow cell for enhanced sensitivity. Anal Chem (2009) 0.81
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma. J Cancer Res Clin Oncol (2013) 0.81
Reprocessing and sterilization of single-use electrophysiological catheters: removal of organic carbon and protein surface residues. J AOAC Int (2009) 0.81
Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH. Am J Clin Pathol (2009) 0.80
2-Aminotetralones: novel inhibitors of MurA and MurZ. Bioorg Med Chem Lett (2008) 0.80
Variation in rates of oestrogen receptor positivity in breast cancer again. BMJ (2002) 0.79
A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH. Histopathology (2010) 0.79
Information technology and hospice palliative care: social, cultural, ethical and technical implications in a rural setting. Inform Health Soc Care (2011) 0.78
Multi-gigabit/s underwater optical communication link using orbital angular momentum multiplexing. Opt Express (2016) 0.78
Can the intestinal dysmotility of critical illness be differentiated from postoperative ileus? Curr Gastroenterol Rep (2011) 0.78
The prevalence and impact of prescription controlled substance use among injured patients at a Level I trauma center. J Trauma Acute Care Surg (2014) 0.78
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists. J Med Chem (2009) 0.78
Suitability of infiltrative lobular breast carcinoma for anti-human epidermal growth factor receptor 2 treatment after the ASCO/CAP and 2009 St Gallen International Expert Consensus meeting. Histopathology (2010) 0.78
Central line-associated blood stream infection in the critically ill trauma patient. Am Surg (2011) 0.78
Synthesis and evaluation of imidazo[1,5-a]pyrazines as corticotropin releasing hormone receptor ligands. Bioorg Med Chem Lett (2002) 0.77
Synthesis and antimicrobial activity of novel substituted ethyl 2-(quinolin-4-yl)-propanoates. Molecules (2013) 0.77
Prognostic factors in ovarian adult granulosa cell tumour. J Clin Pathol (2008) 0.76
Comparison of in vivo clinical performance and shaft temperature and in vitro tissue temperature and transection times between new and reprocessed harmonic scalpels. Surg Laparosc Endosc Percutan Tech (2010) 0.76
Evolution of extended-spectrum beta-lactamases in a MutS-deficient Pseudomonas aeruginosa hypermutator. J Antimicrob Chemother (2006) 0.75
Cell line standards to reduce HER-2/neu assay variation and the potential of automated image analysis to provide more accurate cut points for predicting clinical response to trastuzumab. Am J Clin Pathol (2005) 0.75
Evaluation of target efficiencies for solid-liquid separation steps in biofuels production. Appl Biochem Biotechnol (2010) 0.75
Her-2/neu evaluation in Sister Mary Joseph's nodule from breast carcinoma: a case report and review of the literature. J Cutan Pathol (2009) 0.75
Propagation of modulated optical beams carrying orbital angular momentum in turbid water. Appl Opt (2016) 0.75
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers. Appl Immunohistochem Mol Morphol (2017) 0.75
Arylamidrazones as novel corticotropin releasing factor receptor antagonists. J Med Chem (2002) 0.75
Ecological Assessment of Substance-abuse Experiences (EASE): findings from a new instrument development pilot study. Addict Behav (2005) 0.75
Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies. Appl Immunohistochem Mol Morphol (2015) 0.75
Reprocessed arthroscopic shavers: evaluation of sharpness and function in a cadaver model. Orthopedics (2014) 0.75
Quality: The perspective that counts most. Health Serv J (2012) 0.75
Lasing characteristics of Ho:YAG single crystal fiber. Opt Express (2016) 0.75
Concentric vortex beam amplification: experiment and simulation. Opt Express (2016) 0.75
American Association for the Surgery of Trauma Organ Injury Scale (OIS): past, present, and future. J Trauma Acute Care Surg (2013) 0.75
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in Immunohistochemistry. Appl Immunohistochem Mol Morphol (2016) 0.75
Not All Abdomens Are the Same: A Comparison of Damage Control Surgery for Intra-abdominal Sepsis versus Trauma. Am Surg (2016) 0.75
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics. Appl Immunohistochem Mol Morphol (2017) 0.75
Stapled versus handsewn: A prospective emergency surgery study (SHAPES). An American Association for the Surgery of Trauma multi-institutional study. J Trauma Acute Care Surg (2016) 0.75
Nondestructive quality control of HER2 control cell line sections: the use of interferometry for measuring section thickness and implications for HER2 interpretation on breast tissue. Appl Immunohistochem Mol Morphol (2009) 0.75
Pyrazolo-[1,5-a]-1,3,5-triazine corticotropin-releasing factor (CRF) receptor ligands. Bioorg Med Chem (2003) 0.75
Comparison of performance characteristics between new and reprocessed electrophysiology catheters. J Interv Card Electrophysiol (2007) 0.75